Clinical decision-making during 5 years of antipsychotic treatment

Acta Psychiatrica Scandinavica

Volumn 116, Issue SUPPL. 435, 2007, Pages 17-26

  Levander, S ^a   Eberhard, J ^b,d   Lindstrom E ^c  

^a MALMÖ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical decision making; Longitudinal; Psychosis; Risperidone; Side effects; Symptoms

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; DECISION MAKING; DELUSIONAL DISORDER; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PATIENT ASSESSMENT; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TARDIVE DYSKINESIA;

EID: 35449005978     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2007.01084.x     Document Type: Article

References (36)

1. Hamann J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand 2003 107 : 403 409.
2. Tomasi R, de Girolamo G, Santone G et al. The prescription of psychotropic drugs in psychiatric residential facilities: a national survey in Italy. Acta Psychiatr Scand 2006 113 : 212 23.
3. Bingefors K, Isacson D, Lindstrom E. Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice - a highly individualized therapy. Nord J Psychiatry 2003 57 : 263 269.
4. Chong MY, Tan CH, Fujii S et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004 58 : 61 67.
5. Hamann J, Langer B, Leucht S, Busch R, Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry 2004 161 : 1301 1304.
6. Hamann J, Kolbe G, Cohen R, Leucht S, Kissling W. How do psychiatrists choose among different antipsychotics? Eur J Pharmacol 2005 61 : 851 854.
7. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB, SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 2003 416 : 7 15.
8. Burns T, Christova L, Cooper S et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006 113 : 126 134.
9. Weinmann S, Janssen B, Gaebel W. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. J Clin Psychiatry 2004 65 : 1099 1105.
10. Arnold LM, Strakowski SM, Schwiers ML et al. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res 2004 66 : 169 175.
11. Herbeck DM, West JC, Ruditis I et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 2004 55 : 677 684.
12. Lindström E, von Knorring L. Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations. Acta Psychiatr Scand 1994 89 : 274 278.
13. Pinals DA, Malhotra AK, Missar CD, Pickar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr Res 1996 22 : 215 222.
14. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 2004 51 : 317 324.
15. Goldstein JM, Cohen LS, Horton NJ et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res 2002 110 : 27 37.
16. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry 2001 46 : 534 541.
17. Rettenbacher MA, Hofer A, Eder U et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004 65 : 1211 1218.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. DSM-IV. Washington, DC : APA, 1994.
19. von Knorring L, Lindström E. The Swedish version of the positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability. Acta Psychiatr Scand 1992 86 : 463 468.
20. Lindström E, Eberhard J, Levander S. Five year follow up during antipsychotic treatment; efficacy, safety, functional and social outcome. Acta Psychiatr Scand 2007 116 (Suppl. 435) : 5 16.
21. Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient rated versus clinician rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001 44 : 5 69.
22. Guy W. ECDEU assessment manual for psychopharmacology - revised (DHEW Publ ADM 76-338). Rockville, MD : Department of Helth, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976 : 534 537.
23. Chouinard G, Ross-Chouinard A, Annable L. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980 7 : 233.
24. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983 13 : 177 183.
25. Tansella M, Amaddeo F, Burti L, Lasalvia A, Ruggeri M. Evaluating community-based mental health service focusing on severe mental illness. The Verona experience. Acta Psychiatr Scand 2006 113 (Suppl. 429 90 94.
26. Hofer W, Fleischacker W. Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand 2006 113 : 161 162.
27. Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005 111 (suppl. 427 29 34.
28. Eberhard J, Lindström E, Holstad M, Levander S. Prolactin level during five years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 2007 115 : 268 276.
29. Neovius M, Eberhard J, Lindström E, Levander S. Weight development in patients treated with risperidone: a five year naturalistic study. Acta Psychiatr Scand 2007 115 : 277 285.
30. Eberhard J, Lindström E, Levander S. Tardive dyskinesia and neuroleptics - a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006 21 : 35 42.
31. Wiersma D. Needs of people with severe mental disorders. Acta Psychiatr Scand 2006 113 (Suppl. 429 115 119.
32. Levander S, Eberhard J, Lindström E. Nicotine use and its correlates in patients with psychosis. Acta Psychiatr Scand, 2007 116 (Suppl. 435 27 32.
33. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 2002 22 : 538 540.
34. Jensen J, Nilsson LL, Levander S. Neurocognitive and psychopathological correlates of self-monitoring ability in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004 254 : 312 317.
35. Lysaker PH, Carcione A, Dimaggion G et al. Metacognition amidst narratives of self and illness in schizophrenia: associations with neurocognition, symptoms, insight and quality of life. Acta Psychiatr Scand 2005 112 : 64 71.
36. Fenton W. Shared decision-making: a model for the physician-patient relationship in the 21th century is missing. Acta Psychiatr Scand 2003 107 : 401 402.